Skip to main content
Erschienen in: Graefe's Archive for Clinical and Experimental Ophthalmology 10/2019

Open Access 03.08.2019 | Neuroophthalmology

Efficacy of intensity-modulated radiation therapy for optic nerve sheath meningioma

verfasst von: Hiroyuki Sasano, Keigo Shikishima, Manabu Aoki, Tsutomu Sakai, Yuki Tsutsumi, Tadashi Nakano

Erschienen in: Graefe's Archive for Clinical and Experimental Ophthalmology | Ausgabe 10/2019

Abstract

Purpose

The present study examined the efficacy and complications associated with intensity-modulated radiation therapy (IMRT) for optic nerve sheath meningioma (ONSM) in 15 cases and compared visual function before and after treatment.

Methods

Consecutively diagnosed patients with ONSM treated with IMRT were evaluated from 2012 to 2017. We categorized ONSM with three growth patterns (diffuse, fusiform, or globular). Visual acuity, visual fields, and optic disc findings were assessed before and after IMRT. Ocular and systemic complications were evaluated during and after treatment.

Results

The 15 patients selected for analysis ranged in age from 33 to 77 years. Post-treatment observation periods were 8 to 57 months. After IMRT, tumor enlargement was not detected in any eyes, and tumor reduction was seen in 2 eyes. At final post-treatment follow-up, eyes with fusiform and globular growth maintained better visual acuity compared with pre-treatment, whereas 2 of 5 eyes with diffuse growth showed reduced vision. Five eyes with no apparent optic disc abnormality maintained better visual acuity compared with pre-treatment, whereas 8 of 10 eyes with disc edema and atrophy remained stable or showed reduced vision. Improvements were seen in all 5 eyes with optic discs negative for pre-treatment abnormalities. Final post-treatment visual field abnormalities improved in 11 eyes. All adverse events identified during IMRT improved rapidly during the treatment period.

Conclusion

IMRT for the treatment of ONSM achieved improvement and preserved visual function. In particular, early treatment with IMRT before the appearance of optic disc abnormalities can be more effective for improving visual function.
Hinweise

Electronic supplementary material

The online version of this article (https://​doi.​org/​10.​1007/​s00417-019-04424-w) contains supplementary material, which is available to authorized users.

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Introduction

Optic nerve sheath meningioma (ONSM) is a relatively rare tumor, accounting for 1–2% of all meningiomas [1, 2]. Developing from the arachnoid cap cells of the optic nerve sheath, these benign and slowly progressive tumors cause optic nerve insult through compression and vascular compromise, resulting in severe visual impairment that may lead to blindness [3]. Tumor may grow intracranially through the optic canal to involve the optic chiasm and the contralateral optic nerve. Hence, it is of paramount importance to stop or reverse the growth of the tumor. In the treatment of ONSM, preservation of vision following tumor resection is known to be difficult, because surgery precipitates complications that damage the pial vascular plexus nourishing the optic nerve in many cases, leaving 95% of patients with severe postoperative visual impairment [1]. Surgery is currently indicated when esthetic issues arise following loss of vision or when intracranial tumor extension impacts prognosis for survival. In recent years, stereotactic radiotherapy (SRT), in the broad sense of the term, has been reported as an effective alternative to surgery [4, 5].
Intensity-modulated radiation therapy (IMRT) uses a device such as a multileaf collimator to adjust spatial and temporal radiation intensity and irradiate a precise focal target from multiple directions, thereby achieving optimal dose distribution on a three-dimensional plane. An advanced version of conventional stereotactic radiation therapy that is more effective and non-invasive, this new system reduces exposure to surrounding tissue by enabling modulation of dose intensity within the radiation field. Studies have already shown the advantages of IMRT for treating various intracranial tumors and skull base meningiomas [69]. The optic nerve is highly sensitive to radiation and therefore requires precision radiotherapy to avoid severe radiation-induced optic neuropathy. Detailed research into IMRT outcomes in the treatment of ONSM is lacking. As such, the present study examined the efficacy and complications associated with IMRT for ONSM by applying the technique to a large number of cases and comparing visual function before and after treatment.

Patients and methods

Design

This is single hospital-based, retrospective, observational study.

Patients

Analysis was performed of cases of ONSM that were between February 2012 and August 2017 in the Division of Neuro-Ophthalmology and Ocular Oncology Unit of the Department of Ophthalmology at the Jikei University Hospital. The observation period lasted until October 2017. Diagnosis of ONSM was based on (1) unilateral onset, (2) slowly progressive visual deterioration, (3) positive findings of a relative afferent pupillary defect, (4) optic disc findings, and (5) optic nerve swelling and tram-track sign detected on contrast-enhanced computed tomography (CT) and magnetic resonance imaging (MRI) of the orbit. Although the tram-track sign can be also seen in sarcoidosis, perioptic neuritis, leptomeningeal carcinomatosis, lymphoma, leukemia, and orbital inflammation, these diseases exhibit rapid deterioration. We excluded subjects presenting acute onset or general complications. In this study, all patients had prolonged symptoms up to treatment. Although various morphological typologies have been proposed for tumor growth patterns, the present study categorized patterns into three types as diffuse (tubular), fusiform, or globular according to definitions used in several past studies [1, 3, 10].
IMRT was indicated if patients exhibited at least one of the following clinical features: (1) reduced best-corrected visual acuity (logMAR > 0), (2) visual field abnormality, or (3) intracranial tumor extension. Eyes with visual acuity at or below the ability to count fingers at the initial examination were excluded.

IMRT irradiation

IMRT was performed in the Division of Radiation Therapy at the Jikei University Hospital using a Clinac linear accelerator (Varian Medical Systems, Palo Alto, CA) (Supplement 1). After patients were fixed by immobilization equipment (ShellTM), gross tumor volume (GTV) was delineated using CT and MRI fusion images. GTV was the gross demonstrable extent and location of ONSM. Clinical target volume (CTV) was identical to the GTV. Planning target volume (PTV) was defined as the CTV with a margin of 3 mm. A 2-mm set-up margin was added to the organs at risk, such as the optic nerve, optic chiasm, retina, and pituitary gland. Cone beam CT (CBCT) was performed before each treatment using a 360-degree rotation of the linear accelerator, and CBCT-based GTV was precisely adjusted to planning GTV. Irradiation was provided as 50.4–54.0 Gy in 28–30 fractions, the known tolerance dose for the optic nerve.

Evaluation of treatment efficacy

Visual acuity, visual fields, optic disc, and radiology findings were assessed before and after IMRT. Counting fingers and hand motions were quantified as a logMAR value of − 2. Improvement and deterioration of vision was defined as changes in logMAR values of <− 0.2, and > + 0.2, respectively, whereas stable vision was defined as − 0.2 ≤ logMAR ≤ + 0.2. Visual fields were assessed using Goldmann perimetry performed by an expert examiner with extensive experience. Poor visual acuity due to central scotoma was difficult to evaluate with Humphry field analyzer. In addition, the evaluation of peripheral visual field defect was required. Therefore, we selected Goldmann perimetry first.

Statistical analysis

Using SPSS Statistics version 25 software (IBM, Tokyo, Japan), pre- and post-IMRT measurements of visual acuity were compared using the Wilcoxon signed-rank sum test.

Results

Patients

The 15 patients selected for analysis comprised 14 women and only 1 man, with ages ranging from 33 to 77 years (median, 49 years). Eight right eyes and 7 left eyes were affected, and disease duration from subjective symptoms to treatment ranged from 5 months to 25 years. Minimum and maximum post-treatment observation periods were 8 months, and 4 years and 9 months, respectively (median, 1 year and 11 months). Individual patient data are shown in Table 1.
Table 1
Clinical data of all patients
Case no.
Sex
Affected eye
Age at start of treatment
Symptoms
Disease duration up to start of treatment
Tumor growth pattern
Tumor and extension sites
IMRT dose
1
F
R
52 Y
Reduced visual acuity
10 Y
Fusiform
Anterior predominant
51.0 Gy/30 Fr
2
F
L
46 Y
Discomfort, proptosis
5 M
Fusiform
Posterior predominant
52.2 Gy/29 Fr
3
F
R
39 Y
Pain with eye movement
13 M
Diffuse
 
50.4 Gy/28 Fr
4
F
L
42 Y
Reduced visual acuity
11 M
Globular
Posterior predominant
50.4 Gy/28 Fr
5
F
R
41 Y
Reduced visual acuity
3 Y
Diffuse
Intracranial extension (parasellar region)
51.0 Gy/30 Fr
6
F
R
33 Y
Visual field defect
10 M
Fusiform
Central predominant
51.0 Gy/29 Fr
7
F
R
73 Y
Reduced visual acuity
7 M
Diffuse
 
51.0 Gy/30 Fr
8
M
L
72 Y
Reduced visual acuity
2 Y
Fusiform
Posterior predominant
50.4 Gy/28 Fr
9
F
L
49 Y
Reduced visual acuity
4 Y
Fusiform
 
51.0 Gy/30 Fr
10
F
L
77 Y
Reduced visual acuity, proptosis
10 Y
Fusiform
 
51.0 Gy/30 Fr
11
F
L
59 Y
Reduced visual acuity
25 Y
Fusiform
Anterior predominant
51.0 Gy/30 Fr
12
F
R
49 Y
Reduced visual acuity
11 M
Diffuse
Posterior predominant, Intracranial extension
51.0 Gy/30 Fr
13
F
L
71 Y
Exotropia, proptosis
2 Y
Globular
Posterior predominant
51.0 Gy/30 Fr
14
F
R
56 Y
Reduced visual acuity
3 M
Diffuse
 
51.0 Gy/30 Fr
15
F
R
47 Y
Proptosis
10 Y
Fusiform
Anterior predominant
51.0 Gy/30 Fr
F female, M male, R right, L left, Y years, M months, Gy Gray, Fr fraction

Radiology findings

In terms of ONSM morphology, 5 eyes showed diffuse growth with 2 eyes showing intracranial extension, 8 eyes showed fusiform growth with 1 eye showing intracranial extension, and 2 eyes showed globular growth (Table 1, Figs. 1, 2, and 3). After IMRT, tumor enlargement was not detected in any eyes, and tumor reduction was seen in 2 eyes. Intracranial invasion was not found in cases with intraorbital ONSM after IMRT.

Optic disc findings

Before treatment, swelling, atrophy, and optociliary shunt vessels were observed in the optic discs of 7, 3, and 5 eyes, respectively, whereas no abnormalities were found in 5 eyes (Table 2). After treatment, optic disc atrophy was detected in 3 eyes and anterior ischemic optic neuropathy was detected in 1 eye. No changes in optic discs findings were observed in the remaining 11 eyes. In addition, no post-treatment changes were seen in the 5 eyes with optic discs negative for pre-treatment abnormalities.
Table 2
Changes in optic disc findings from pre- to post-treatment
Case no.
Optic disc finding pre-treatment
OCSV
Optic disc finding post-treatment
1
Swelling
+
Swelling
2
Normal
Normal
3
Swelling
+
Atrophy
4
Normal
Normal
5
Atrophy
Atrophy
6
Normal
Normal
7
Swelling
+
Atrophy, ION
8
Atrophy
Atrophy
9
Swelling
Atrophy
10
Normal
Normal
11
Swelling
+
Swelling
12
Normal
Normal
13
Atrophy
+
Atrophy
14
Swelling
Atrophy
15
Swelling
Swelling
OCSV optociliary shunt vessel, ION ischemic optic neuropathy

Visual acuity

Immediate post-treatment visual acuity (IPostVA), which reflects effects and complications immediately after 28 to 30 times radiation treatment, improved in 5 eyes, remained stable in 9 eyes, and deteriorated in 1 eye (Table 3). No significant difference between pre-treatment visual acuity (PreVA) and IPostVA was detected (p = 0.050). Final post-treatment visual acuity (FPostVA) improved in 7 eyes, remained stable in 4 eyes, and deteriorated in 4 eyes. No significant difference between PreVA and FPostVA was detected (p = 0.330).
Table 3
Changes in visual acuity from pre- to post-treatment
Case no.
logMAR pre-treatment
logMAR post-treatment
Change (post-pre)
logMAR final
Change (final-pre)
Final observation period
1
0.22
0.15
− 0.0669
No change
0.05
− 0.1761
No change
44 M
2
0.30
− 0.08
− 0.3802
Improved
0.00
− 0.3010
Improved
46 M
3
1.70
1.70
0.0000
No change
2.00
0.3010
Deteriorated
47 M
4
0.52
− 0.08
− 0.6021
Improved
0.00
− 0.5229
Improved
52 M
5
2.00
1.70
− 0.3010
Improved
1.70
− 0.3010
Improved
58 M
6
0.40
− 0.08
− 0.4771
Improved
− 0.18
− 0.5740
Improved
27 M
7
0.40
0.30
− 0.0969
No change
2.00
1.6021
Deteriorated
32 M
8
0.30
0.22
− 0.0792
No change
0.52
0.2218
Deteriorated
24 M
9
0.22
0.70
0.4771
Deteriorated
1.22
1.0000
Deteriorated
21 M
10
0.52
0.30
− 0.2218
Improved
0.22
− 0.3010
Improved
21 M
11
1.00
0.82
− 0.1761
No change
1.05
0.0458
No change
12 M
12
0.30
0.15
− 0.1461
No change
− 0.08
− 0.3802
Improved
21 M
13
0.05
0.05
0.0000
No change
0.15
0.1091
No change
11 M
14
0.82
1.00
0.1761
No change
0.52
− 0.3010
Improved
13 M
15
0.40
0.22
− 0.1761
No change
0.22
− 0.1761
No change
8 M
M months
*Hand motion (HM) and no light perception (NLP) are equivalent to logMAR = 2.00
Among diffuse tumor, IPostVA improved in 1 eye and remained stable in 4 eyes, whereas FPostVA improved in 3 eyes, and deteriorated in 2 eyes (Fig. 4a). Among fusiform tumor, IPostVA improved in 3 eyes, remained stable in 4 eyes, and deteriorated in 1 eye, whereas FPostVA improved in 3 eyes, remained stable in 3 eyes, and deteriorated in 2 eyes (Fig. 4b). Among globular tumor IPostVA improved and remained stable in 1 eye each, whereas FPostVA improved and remained stable in 1 eye each (Fig. 4c). At final post-treatment follow-up, eyes with fusiform and globular growth maintained better visual acuity compared with pre-treatment levels, whereas 2 of 5 eyes with diffuse growth showed reduced vision (40%) (Fig. 4d).
Among the 5 eyes negative for optic disc abnormalities, improvement was seen in 4 eyes, whereas 1 eye remained stable (Fig. 5a). Among the 7 cases of optic disc swelling, IPostVA remained stable in 6 eyes and deteriorated in 1 eye, whereas FPostVA improved in 1 eye, remained stable in 3 eyes, and deteriorated in 3 eyes (Fig. 5b). Among the three cases of optic disc atrophy, IPostVA improved in 1 eye and remained stable in 2 eyes, whereas FPostVA improved, remained stable, and deteriorated in 1 eye each (Fig. 5c). Figure 5d compares mean PreVA, IPostVA, and FPostVA among the three optic disc patterns (no apparent abnormality, edema, and atrophy). In all three patterns, vision improved immediately after treatment. At final post-treatment follow-up, all 5 eyes with no apparent abnormality maintained better visual acuity compared with pre-treatment levels, whereas 6 of 7 eyes with edema and 2 of 3 eyes with atrophy remained stable or showed reduced vision.

Visual field

Various visual field abnormalities were found to have accompanied ONSM (supplement 2). As for affected eyes, after treatment, abnormalities improved in 14 eyes. Improvements were seen in all 5 eyes with optic discs negative for pre-treatment abnormalities. Final post-treatment visual field abnormalities improved in 11 eyes, deteriorated in 3 eyes, and were not assessed in 1 eye (Table 4). As for fellow eyes, scotomas were observed in 3 eyes before treatment, but improved after treatment.
Table 4
Changes of affected eye in visual field from pre- to post-treatment
Case no.
Visual field pre-treatment
Visual field post-treatment
Visual field final
1
General reduction of sensitivity
Improved
Deteriorated (scotoma)
2
Inferior visual field constriction
Improved
Improved
3
Preservation of temporal and inferior temporal fields only
Improved (slight increase in sensitivity)
Deteriorated
4
Central scotoma, superior scotoma
Improved (central scotoma disappearance, superior scotoma reduction)
Improved
5
Preservation of superior field only
Improved
Improved
6
Temporal field loss, inferior field constriction
Improved
Improved
7
Central scotoma, paracentral scotoma, inferior field constriction
Improved (central scotoma disappearance)
Deteriorated
8
Superior paracentral scotoma, nasal field constriction
Improved (of nasal field)
Improved
9
No data
Inferior field constriction
Not evaluable
10
Inferior paracentral scotoma
Improved (paracentral scotoma reduction)
Improved
11
Preservation of temporal field only
Improved (remaining temporal field)
Improved
12
Inferior field loss
Improved (of inferior field)
Improved
13
Temporal field loss
Improved (temporal field expansion)
Improved
14
Generalized visual field constriction
Improved
Improved
15
Superior scotoma, nasal scotoma
Improved (nasal scotoma disappearance)
Improved

Adverse events

Adverse events identified during IMRT included skin redness in 3 patients, lacrimation in 3 patients, eye/retrobulbar pain in 4 patients, heaviness in the rear of the eye in 2 patients, headache in 4 patients, heavy-headedness in 1 patient, nausea in 2 patients, light-headedness in 2 patients, dizziness in 2 patients, fatigue/malaise in 11 patients, and dryness in the nose in 1 patient. All adverse events improved rapidly during the IMRT treatment period.
One eye (case 7) with a diffuse growth pattern that had maintained visual acuity immediately after IMRT developed an acute case of ischemic optic neuropathy on day 127 post-treatment. Another eye (case 1) showed reduced visual acuity due to a cataract on day 653. No cases of systemic complications including endocrine disorders or hair loss were observed.

Discussion

In the context of visual function, increases in visual acuity from pre-treatment levels were achieved immediately after IMRT, and the absence of significant differences between PreVA and FPostVA indicates that vision was preserved in the overall sample. Furthermore, following IMRT, visual field improvements were seen in 14 eyes immediately after IMRT.
Although comparison of PreVA and IPostVA showed that IMRT was effective for all three tumor growth patterns, FPostVA of the entire sample was found to have decreased from IPostVA (Fig. 4a–c). FPostVA tended to decrease from PreVA among eyes with diffuse tumors, but it tended to increase among eyes with fusiform and globular tumors. ONSM is characterized by progressive visual loss, and although one study demonstrated that visual function prognosis is the worst in cases of diffuse tumor growth exhibiting apical expansion [3]. Other research into the prognoses of individual growth patterns is still lacking. The FPostVA findings of the present study suggest that IMRT is favorably indicated for fusiform and globular tumors. In contrast, it was difficult to reach any conclusions in terms of diffuse tumors, because the present sample was not compared with a control group undergoing natural disease progression. Therefore, the effectiveness of IMRT for treating diffuse tumors remains a priority moving forward. IMRT can be performed with high precision by adjusting to the shape of the lesion. Therefore, the difference in treatment effect among tumor growth pattern could result from the extent of the damage or preservation of the optic nerve depending on the shape of the tumors rather than the difference in the dose distribution.
With respect to optic disc findings, of the 5 eyes negative for pre-treatment optic disc abnormalities, there were significant improvements in IPostVA and field performance regardless of the degree of visual loss and visual field impairment present before IMRT; a decline in FPostVA compared with IPostVA was observed in only 1 eye in the present study. On the other hand, post-treatment visual acuity and field performance for 10 eyes with pre-treatment optociliary shunt vessels and optic disc swelling and atrophy were inconsistent and ranged from improvement to no change to deterioration. Since eyes negative for optic disc abnormalities showed only a small reduction in FPostVA (i.e., late-stage vision), we believe that early treatment with IMRT before the appearance of atrophy, swelling, and other types of optic disc insult may lead to better outcomes for visual function.
In terms of SRT for ONSM, it has been reported that no relationship exists between the timing of radiotherapy and prognosis [10], that better visual acuity performance can be gained with early treatment [11], that treatment efficacy is greater in eyes with PreVA ranging from 20/40 to 20/30 [12], and that treatment is indicated when visual acuity is ≤ 20/40 or when visual field impairment is detected [13].
Because the present study showed that treatment was effective regardless of the degree of visual loss, and FPostVA was better among eyes administered IMRT before developing optic disc impairment, we believe that early IMRT is desirable when patients experience subjectively reduced vision and visual field disturbances.
A search of the literature identified studies that examined the efficacy of IMRT for treating ONSM, and there were only 25 cases in total [7, 8, 11, 1418]. Furthermore, only 5 cases in total could be followed up for more than 5 years after IMRT as monotherapy [16, 18]. According to these studies, IMRT resulted in visual acuity improvement and stability in 19 eyes, no response in 3 eyes, and deterioration in 3 eyes, and it was associated with late adverse events, including lens opacification in 3 patients, dry eye in 3 patients, radiation-induced retinopathy in 2 patients with diabetes mellitus, keratitis in 2 patients, and blepharitis, otitis media with effusion, and early menopause in 1 patient each. The number of eyes examined in the present study is so far the greatest in a single institute.
Comparing different types of stereotactic irradiation techniques, SRT uses fractionated irradiation to deliver a uniform dose within the radiation field, IMRT delivers a non-uniform dose that mitigates exposure to proximal organs at risk, and stereotactic radiosurgery delivers a uniform dose within the radiation field in a single session. IMRT allows for more non-invasive treatment, because dose intensity can be modulated within the targeted field, thus lessening irradiation of surrounding tissue.
Various studies have reported the advantages of SRT for treating ONSM [19, 20], but they have also reported both ocular and systemic complications. IMRT is anticipated to achieve better local tumor control and visual improvement with a lower complication rate than conventional SRT [21, 22]. Acute complications observed in the present study disappeared soon after completion of IMRT. In terms of late complications, 1 eye developed ischemic optic neuropathy after IMRT. Although hypopituitarism after SRT for ONSM is reported [21], there were no symptoms related to this complication in the present study.
We showed the efficacy of IMRT in a large number of cases in a single facility. However, several limitations of this study should be acknowledged. First, because of the various follow-up period, the time when the final visual function was evaluated is different in each case. Second, due to the short observation period, the late complications of IMRT have not been evaluated. The longest observation period is 4 years and 9 months in this study.
There are few reports of long-term prognosis of IMRT because IMRT is a novel radiation therapy compared with conventionally fractionated stereotactic radiotherapy and conformal radiotherapy. We will continue to follow up the cases and evaluate long-term post-treatment visual function and complications in further study.
IMRT for the treatment of ONSM achieved improvement and preservation of visual function. We believe that early treatment with IMRT before the appearance of optic disc abnormalities can be more effective for improving visual function, particularly among patients with fusiform and globular growth patterns. Moreover, the risk of serious post-treatment complications is considered low.

Compliance with ethical standards

Conflict of interest

Hiroyuki Sasano declares that he has no conflict of interest. Keigo Shikishima has received speaker honorariums from Santen Pharmaceutical Co., Ltd., Senju Pharmaceutical Co., Ltd., Johnson and Johnson K.K. and Cosmic Corp. Manabu Aoki declares that he has no conflict of interest. Tsutomu Sakai declares that he has no conflict of interest. Yuki Tsutsumi declares that she has no conflict of interest. Tadashi Nakano has received research grants from Crewt Medical Systems Inc., Kowa Pharmaceutical Co., Ltd., Tomey Corp, Senju Pharmaceutical Co., Ltd., Otsuka Pharmaceutical Co., Ltd., Merck Sharp and Dohme K.K., Pfizer Inc., Alcon Japan, Ltd., Santen Pharmaceutical Co., Ltd., Nidek Co., Ltd., Johnson and Johnson K.K. and Bayer Yakuhin, Ltd.

Ethical approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the Jikei University School of Medicine Ethics Committee (No. 272488133) and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.
Informed consent was obtained from all individual participants included in the study.
Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Unsere Produktempfehlungen

e.Med Interdisziplinär

Kombi-Abonnement

Für Ihren Erfolg in Klinik und Praxis - Die beste Hilfe in Ihrem Arbeitsalltag

Mit e.Med Interdisziplinär erhalten Sie Zugang zu allen CME-Fortbildungen und Fachzeitschriften auf SpringerMedizin.de.

Gräfes Archiv

Online-Abonnement

Anhänge

Electronic supplementary material

Literatur
8.
Zurück zum Zitat Grant W 3rd, Cain RB (1998) Intensity modulated conformal therapy for intracranial lesions. Med Dosim 23:237–241CrossRefPubMed Grant W 3rd, Cain RB (1998) Intensity modulated conformal therapy for intracranial lesions. Med Dosim 23:237–241CrossRefPubMed
9.
Zurück zum Zitat Uy NW, Woo SY, Teh BS, Mai WY, Carpenter LS, Chiu JK, Lu HH, Gildenberg P, Trask T, Grant WH, Butler EB (2002) Intensity-modulated radiation therapy (IMRT) for meningioma. Int J Radiat Oncol Biol Phys 53:1265–1270CrossRefPubMed Uy NW, Woo SY, Teh BS, Mai WY, Carpenter LS, Chiu JK, Lu HH, Gildenberg P, Trask T, Grant WH, Butler EB (2002) Intensity-modulated radiation therapy (IMRT) for meningioma. Int J Radiat Oncol Biol Phys 53:1265–1270CrossRefPubMed
12.
Zurück zum Zitat Landert M, Baumert BG, Bosch MM, Lutolf UM, Landau K (2005) The visual impact of fractionated stereotactic conformal radiotherapy on seven eyes with optic nerve sheath meningiomas. J Neuroophthalmol 25:86–91CrossRefPubMed Landert M, Baumert BG, Bosch MM, Lutolf UM, Landau K (2005) The visual impact of fractionated stereotactic conformal radiotherapy on seven eyes with optic nerve sheath meningiomas. J Neuroophthalmol 25:86–91CrossRefPubMed
13.
Zurück zum Zitat Kennerdell JS, Maroon JC, Malton M, Warren FA (1988) The management of optic nerve sheath meningiomas. Am J Ophthalmol 106:450–457CrossRefPubMed Kennerdell JS, Maroon JC, Malton M, Warren FA (1988) The management of optic nerve sheath meningiomas. Am J Ophthalmol 106:450–457CrossRefPubMed
14.
Zurück zum Zitat Lee AG, Woo SY, Miller NR, Safran AB, Grant WH, Butler EB (1996) Improvement in visual function in an eye with a presumed optic nerve sheath meningioma after treatment with three-dimensional conformal radiation therapy. J Neuroophthalmol 16:247–251PubMed Lee AG, Woo SY, Miller NR, Safran AB, Grant WH, Butler EB (1996) Improvement in visual function in an eye with a presumed optic nerve sheath meningioma after treatment with three-dimensional conformal radiation therapy. J Neuroophthalmol 16:247–251PubMed
20.
Zurück zum Zitat Pacelli R, Cella L, Conson M, Tranfa F, Strianese D, Liuzzi R, Solla R, Farella A, Salvatore M, Bonavolonta G (2011) Fractionated stereotactic radiation therapy for orbital optic nerve sheath meningioma - a single institution experience and a short review of the literature. J Radiat Res 52:82–87CrossRefPubMed Pacelli R, Cella L, Conson M, Tranfa F, Strianese D, Liuzzi R, Solla R, Farella A, Salvatore M, Bonavolonta G (2011) Fractionated stereotactic radiation therapy for orbital optic nerve sheath meningioma - a single institution experience and a short review of the literature. J Radiat Res 52:82–87CrossRefPubMed
Metadaten
Titel
Efficacy of intensity-modulated radiation therapy for optic nerve sheath meningioma
verfasst von
Hiroyuki Sasano
Keigo Shikishima
Manabu Aoki
Tsutomu Sakai
Yuki Tsutsumi
Tadashi Nakano
Publikationsdatum
03.08.2019
Verlag
Springer Berlin Heidelberg
Erschienen in
Graefe's Archive for Clinical and Experimental Ophthalmology / Ausgabe 10/2019
Print ISSN: 0721-832X
Elektronische ISSN: 1435-702X
DOI
https://doi.org/10.1007/s00417-019-04424-w

Weitere Artikel der Ausgabe 10/2019

Graefe's Archive for Clinical and Experimental Ophthalmology 10/2019 Zur Ausgabe

Neu im Fachgebiet Augenheilkunde

Ophthalmika in der Schwangerschaft

Die Verwendung von Ophthalmika in der Schwangerschaft und Stillzeit stellt immer eine Off-label-Anwendung dar. Ein Einsatz von Arzneimitteln muss daher besonders sorgfältig auf sein Risiko-Nutzen-Verhältnis bewertet werden. In der vorliegenden …

Operative Therapie und Keimnachweis bei endogener Endophthalmitis

Vitrektomie Originalie

Die endogene Endophthalmitis ist eine hämatogen fortgeleitete, bakterielle oder fungale Infektion, die über choroidale oder retinale Gefäße in den Augapfel eingeschwemmt wird [ 1 – 3 ]. Von dort infiltrieren die Keime in die Netzhaut, den …

Bakterielle endogene Endophthalmitis

Vitrektomie Leitthema

Eine endogene Endophthalmitis stellt einen ophthalmologischen Notfall dar, der umgehender Diagnostik und Therapie bedarf. Es sollte mit geeigneten Methoden, wie beispielsweise dem Freiburger Endophthalmitis-Set, ein Keimnachweis erfolgen. Bei der …

So erreichen Sie eine bestmögliche Wundheilung der Kornea

Die bestmögliche Wundheilung der Kornea, insbesondere ohne die Ausbildung von lichtstreuenden Narben, ist oberstes Gebot, um einer dauerhaften Schädigung der Hornhaut frühzeitig entgegenzuwirken und die Funktion des Auges zu erhalten.   

Update Augenheilkunde

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.